Blockchain Registration Transaction Record

HeartBeam to Report Q1 2026 Results, Updates on Arrhythmia Launch

HeartBeam (NASDAQ: BEAT) announces Q1 2026 conference call and updates on commercial launch of 3D ECG technology for arrhythmia assessment and heart attack detection.

HeartBeam's innovative 3D ECG technology, which received FDA clearance for arrhythmia assessment and 12-lead synthesis, represents a paradigm shift in cardiac care. By enabling portable, cable-free ECG monitoring outside medical facilities, it promises earlier detection of heart attacks and improved management of arrhythmias, potentially reducing hospital visits and healthcare costs. For investors and patients, this news matters because it signals progress toward commercializing a disruptive technology that could redefine cardiac health management.